

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
19 June 2025 (19.06.2025)



(10) International Publication Number
WO 2025/128839 A1

- (51) International Patent Classification:
A61P 5/14 (2006.01) *C07K 16/28* (2006.01)
- (21) International Application Number:
PCT/US2024/059796
- (22) International Filing Date:
12 December 2024 (12.12.2024)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
63/609,824 13 December 2023 (13.12.2023) US

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

- (71) Applicant: **HORIZON THERAPEUTICS IRELAND DAC** [IE/IE]; Pottery Road, Dún Laoghaire, Dublin, A96 F2A8 (IE).
- (72) Inventors: **BORROK III, Martin Jack**; c/o Horizon Therapeutics Ireland DAC, Pottery Road, Dún Laoghaire, Dublin, A96 F2A8 (IE). **WARD, Christopher Davidson**; c/o Horizon Therapeutics Ireland DAC, Pottery Road, Dún Laoghaire, Dublin, A96 F2A8 (IE).
- (74) Agent: **PURCELL, Angela L.**; c/o AMGEN INC., One Amgen Center Drive, Law Dept. - Patent Operations, M/S 28-5-A, Thousand Oaks, California 91320-1799 (US).
- (81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.
- (84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: METHODS FOR THE TREATMENT OF THYROID EYE DISEASE WITH ANTI IGF-IR ANTAGONISTIC ANTIBODIES

(57) Abstract: Described herein are methods of treating or reducing the severity of thyroid eye disease (TED), as well as antibodies that bind and inhibit signaling through the insulin-like growth factor receptor 1, useful in the methods.

WO 2025/128839 A1